Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 20/20 | 0.76 |
| ▸ | KDR | P35968 | 20/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 17/20 | 0.76 |
| ▸ | FLT4 | P35916 | 12/20 | 0.76 |
| ▸ | EGFR | P00533 | 10/20 | 0.76 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.74 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.66 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1467151 | 0.99 | FLT1 (0.75) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL1469934 | 0.95 | FLT1 (0.78) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL1467073 | 0.90 | KDR (0.74) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL1468310 | 0.89 | FLT1 (0.85) | FLT1KDRFGFR1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL1467696 | 0.88 | FLT1 (0.75) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL1887242 | 0.88 | FLT1 (0.71) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL7870684 | 0.88 | FLT1 (0.90) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL7864752 | 0.88 | FLT1 (0.83) | FLT1KDRFGFR1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL1885543 | 0.87 | FLT1 (0.70) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL7866069 | 0.87 | FLT1 (0.82) | FLT1KDRFGFR1FLT4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42353-E1 | Quinazoline derivatives and pharmaceutical compositions containing them | ASTRAZENECA UK LIMITED (GB) | 2011-05-10 | — | — | US | claimed |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 2011-03-24 | — | — | US | claimed |
| JP-3438818-B2 | — | — | 2003-08-18 | — | — | JP | claimed |
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA LIMITED | 2002-11-21 | — | — | US | claimed |
| EP-0929530-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2002-11-20 | — | — | EP | claimed |
| US-6414148-B1 | PRODUCE ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT IN WARM-BLOODED ANIMALS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | claimed |
| JP-2001500891-A | — | — | 2001-01-23 | — | — | JP | claimed |
| EP-0929530-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | claimed |
| WO-1998013354-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | claimed |
| US-RE42353-E1 | Quinazoline derivatives and pharmaceutical compositions containing them | ASTRAZENECA UK LIMITED (GB) | 2011-05-10 | — | — | US | disclosed |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| US-20050239777-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA PHARMA S.A. (FR) | 2005-10-27 | — | — | US | disclosed |
| US-6897210-B2 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| US-20040242574-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED | 2004-12-02 | — | — | US | disclosed |
| US-6673803-B2 | FOR TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS; ACTIVITY AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | ZENECA LIMITED (GB) | 2004-01-06 | — | — | US | disclosed |
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA LIMITED | 2002-11-21 | — | — | US | disclosed |
| EP-0929530-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2002-11-20 | — | — | EP | disclosed |
| US-6414148-B1 | PRODUCE ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT IN WARM-BLOODED ANIMALS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| EP-0929530-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013354-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242574-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, FLT1, NR5A1 | FLT1 2/4885KDR 6/4885FGFR1 177/4885 |
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | CNKSR1, FLT1, VEGFA | FLT1 2/4885KDR 4/4885FGFR1 195/4885 |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NR5A1, NR5A2, CNKSR1 | FLT1 8/4885KDR 13/4885FGFR1 146/4885 |
| US-20050239777-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | NR5A1, NR5A2, CNKSR1 | FLT1 8/4885KDR 13/4885FGFR1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.